Clinical Trial Update: Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating gabapentin for post-COVID-19 olfactory dysfunction has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Olfactory Disorders

Drugs mentioned

• Gabapentin (Gabapentin)

Snippet

Sponsor: Washington University School of Medicine | Conditions: COVID-19, Olfactory Disorder | Phase 2 | Status: COMPLETED | Results posted: 2025-03-04